Current therapeutic approaches to depression fail for millions of patients due to lag in clinical response and non-adherence. Here we provide new support for the antidepressant effect of an anesthetic drug, ketamine, by Inverse-Frequency Analysis of eight million reports from the FDA Adverse Effect Reporting System. The results of the examination of population scale data revealed that patients who received ketamine had significantly lower frequency of reports of depression than patients who took any other combination of drugs for pain. The analysis also revealed that patients who took ketamine had significantly lower frequency of reports of pain and opioid induced side effects, implying ketamine’s potential to act as a beneficial adjunct agent in pain management pharmacotherapy. Further, the Inverse-Frequency Analysis methodology provides robust statistical support for the antidepressant action of other currently approved therapeutics including diclofenac and minocycline.
Popular Blog Posts
End The Stigma!
Lady Gaga and Bradley Cooper did a masterful remake of “A Star is Born”, now in theaters. We highly…
Dr. Sanjay Gupta on CNN: “Ketamine offers lifeline for people with severe depression, suicidal thoughts”
In this post, a Wisconsin man who had been on the brink of suicide, told CNN’s Sanjay Gupta how…
The Resurgence of Psychedelics in Medicine
There has been a flurry of articles in the media recently touting the successful use of psychedelics in medicine.…
Ketamine Infusions Provide Effective Relief for Severe Chronic Headache
Medical research is revealing more and more applications for ketamine, the old drug being used in new ways. Just…
New Insight Into How Ketamine Works in Depression
Ketamine exerts an initial antidepressant effect by blocking the N-methyl-D-aspartate receptor (NMDAR), and the ketamine metabolite hydroxynorketamine (HNK) may extend…